Healthcare Mar 09, 2022 09:46 AM (GMT+8) · EqualOcean
Recently, zhenzhun Biotechnology (Shanghai) Co., Ltd., a leading enterprise of digital PCR, completed a round of financing of more than 100 million yuan, which was exclusively invested by Huiyuan capital, a professional investment institution in the medical industry. Huiyuan capital will enable enterprises to accelerate the popularization and promotion of digital PCR in life science and clinical fields by introducing rich industrial resources. This round of financing will be used for clinical registration, market promotion, large-scale production of microcavity chip digital PCR products and R & D of a variety of kit products. Digital PCR technology is known as the "third generation PCR technology". Compared with the traditional real-time fluorescent PCR, digital PCR can realize the absolute quantification of nucleic acid copy number, and the detection sensitivity can be as high as 0.01%. It has a wide application prospect. After more than ten years of development, in a variety of technical paths, "microcavity chip" has gradually become the mainstream technical route of digital PCR because of its excellent uniformity, stability and efficiency. It is also the technical direction chosen by many international giants.

This text is a result of machine translation.